Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience.

Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience. J Viral Hepat. 2018 Dec 21;: Authors: Ramachandran J, Budd S, Slattery H, Muller K, Mohan T, Cowain T, Tilley E, Baas A, Wigg L, Alexander J, Woodman R, Kaambwa B, Wigg A Abstract Screening and treatment for hepatitis C virus (HCV) infection were not prioritised in psychiatric patients due to adverse neuropsychiatric effects of interferon therapy despite reports of high prevalence. However, with the safe new antiviral drugs HCV eradication has become a reality in these patients. The aim of this study was to report HCV seroprevalence, risk factors and treatment model in an Australian cohort. This prospective study involved patients admitted to four inpatient psychiatric units, from December 2016 to December 2017. After pre-test counselling and consent, HCV testing was done; information on risk factors collected. 260 patients (70% male), median age 44 years (IQR 24), were studied. The HCV seroprevalence was 10.8% (28/260) with 95% CI 7-15. Independent predictors of HCV positivity were injection drug use (p
Source: Rural Remote Health - Category: Rural Health Authors: Tags: J Viral Hepat Source Type: research

Related Links:

The use of interferon-based regimens in chronic hepatitis C-infected children 3-6 years of age is limited due to side effects. Does sofosbuvir/ledipasvir therapy provide a safe alternative?Liver International
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Abstract NPs should be given a more significant role in this effort. PMID: 32079778 [PubMed - in process]
Source: The American Journal of Nursing - Category: Nursing Authors: Tags: Am J Nurs Source Type: research
Some victims ’ diagnosis of HIV and hepatitis C was withheld for years, hearing toldThe guilt of infected blood donors and the anger of victims whose diagnosis of HIV and hepatitis C was withheld from them for years has emerged as evidence given in secret was read out to a public hearing in London.On Monday, witnesses who did not want to appear in person had their testimony delivered by intermediaries who interviewed them for the infected blood inquiry. It is examining how as many as 30,000 people became severely ill after being givencontaminated blood products by the NHS in the 1970s and 80s; many have since died.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Contaminated blood scandal UK news NHS Health Society Infectious diseases Science Source Type: news
Funding Opportunity RFA-AI-20-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Although immune checkpoint inhibitors (ICIs) have improved survival in many patients with non-small cell lung cancer (NSCLC), [1] our understanding of the safety and efficacy of these therapies in certain populations is limited. Patients with past2 or chronic [1] hepatitis B (HBV) or hepatitis C virus (HCV) infections, for example, have been excluded from most of the pivotal phase 3 immunotherapy clinical trials in lung cancer [1,2], so there is a paucity of data both on the risks of viral reactivation or flare, and on the rates of hepatotoxicity in these patients after treatment with ICIs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 22 February 2020Source: Preventive MedicineAuthor(s): Nasser Sharareh, Rachel Hess, Scott White, Angela Dunn, Phillip M. Singer, Jerry CochranAbstractAfter the 2014–2015 HIV outbreak in Scott County, Indiana, United States Centers for Disease Control and Prevention (CDC) conducted a nationwide analysis to identify vulnerable counties to an outbreak of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) and prevent such an outbreak in the future. We developed a jurisdiction-level vulnerability assessment for HCV infections associated with injection drug use (IDU) in Utah.We us...
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Publication date: Available online 21 February 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Kellie Young, Benny Liu, Taft Bhuket, Robert J. WongAbstractBackground &AimsDirect-acting antivirals (DAAs) are expected to improve outcomes for hepatitis C virus (HCV) patients following liver transplantation (LT). We aim to evaluate trends in post-LT outcomes with availability of DAAs.MethodsWe retrospectively evaluated U.S. adults transplanted from 1/1/2002 – 3/31/2018 using the United Network for Organ Sharing registry, stratified by pre-DAA (1/1/2002-12/31/2013) vs. post-DAA (1/1/2014-3/31/201...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: April 2020Source: Cancer Epidemiology, Volume 65Author(s): Ahmed Arafa, Ehab S. Eshak, Tarek A. Abdel Rahman, Manal M. AnwarAbstractBackgroundA growing body of evidence has suggested an association between Hepatitis C virus (HCV) infection and risk of pancreatic cancer (PAC). Herein, we conducted a meta-analysis of available evidence to explore this association.MethodsWe systematically retrieved studies that investigated the association between HCV infection and risk of PAC. Pooled odds ratio (OR) with corresponding 95 % confidence interval (CI) of PAC for patients with HCV infection was calculated using ...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
An estimated 4.1 million people in the United States are infected with hepatitis C virus (HCV). In 2014, the Hepatitis C Community Alliance to Test and Treat (HepCCATT) collaborative was formed to address hepatitis C in Chicago. From 2014 to 2017, the HepCCATT Case Management Program case managed 181 HCV-infected people and performed on-site capacity building at a 6-site community health center (CHC) that produced codified protocols, which were translated into a telehealth program to build capacity within CHCs to deliver hepatitis C care. HepCCATT's innovative approach to addressing multilevel barriers is a potential model...
Source: Family and Community Health - Category: Primary Care Tags: Original Articles Source Type: research
ConclusionsThe incidence of HCC and progression of liver disease was evident in PR responders during the long-term follow-up period, but the risk level was low. Cirrhotic responders were more vulnerable to develop HCC post SVR24 compared with non-cirrhotic ones. HCV recurrence was rare in responders with SVR24 who had corrected their risky behaviors.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
More News: Australia Health | Brain | Hepatitis | Hepatitis C | Men | Neurology | Nurses | Nursing | Psychiatry | Rural Health | Study